| Autor: |
Cortés González, Miguel A., Högnäsbacka, Antonia A., Halldin, Christer, Schou, Magnus |
| Předmět: |
|
| Zdroj: |
Journal of Labelled Compounds & Radiopharmaceuticals; 5/30/2024, Vol. 67 Issue 6, p245-249, 5p |
| Abstrakt: |
AZD4747 is a KRASG12C inhibitor recently shown to cross the non‐human primate blood‐brain barrier efficiently. In the current study, a GMP‐compliant production of [11C]AZD4747 was developed to enable PET studies in human subjects. The validated procedure afforded [11C]AZD4747 as an injectable solution in good radioactivity yield (1656 ± 532 MBq), excellent radiochemical purity (100%), and a molar activity of 77 ± 13 GBq/μmol at the end of the synthesis, which took 46 ± 1 min from the end of the bombardment. Quality control on the final product was performed satisfactorily and met all acceptance criteria. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text